Скачать или смотреть MASH Explained: Disease Burden, Diagnosis & the Role of Resmetirom (REMASH)

Metabolic dysfunction–associated steatohepatitis (MASH) is a serious and progressive liver disease, affecting a significant proportion of adults worldwide. Often associated with conditions such as obesity, diabetes, hypertension, hypothyroidism, and dyslipidemia, MASH can silently progress due to vague symptoms in its early stages.

This video explains:

The global burden of MASLD and MASH

Why early diagnosis and timely treatment are critical

The pathophysiology of MASH, including impaired THR-β signaling

The mechanism of action of resmetirom, a selective THR-β agonist

Clinical benefits such as reduction in liver fat, inflammation, and fibrosis

Dosing, safety profile, and patient considerations

Resmetirom is the first USFDA-approved medication for adults with non-cirrhotic MASH with moderate to advanced liver fibrosis, offering a disease-modifying approach rather than symptom management alone.

Azista announces the launch of REMASH, aimed at improving access to approved therapy for eligible patients with MASH.

▶ This content is intended for educational purposes and for healthcare awareness.